Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Reducing Right Ventricular Failure in Pulmonary Arterial Hypertension (RELIEVE-PAH)

NCT: NCT03838445 · RECRUITING

NCT IDNCT03838445
StatusRECRUITING
Start Date2020-02-14
Completion2031-12-31

Brief Summary

The objectives of the RELIEVE-PAH study are to obtain first-in-human experience with the study device in patients with severe pulmonary arterial hypertension, including evidence of initial safety, device performance and possible signals of clinical effectiveness.

Frequently Asked Questions

What is Reducing Right Ventricular Failure in Pulmonary Arterial Hypertension (RELIEVE-PAH)?

Reducing Right Ventricular Failure in Pulmonary Arterial Hypertension (RELIEVE-PAH) is a clinical trial registered under NCT03838445. Current status: RECRUITING.

What is the status of NCT03838445?

The current status of NCT03838445 (Reducing Right Ventricular Failure in Pulmonary Arterial Hypertension (RELIEVE-PAH)) is: RECRUITING.

When did Reducing Right Ventricular Failure in Pulmonary Arterial Hypertension (RELIEVE-PAH) start?

Reducing Right Ventricular Failure in Pulmonary Arterial Hypertension (RELIEVE-PAH) started on 2020-02-14.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑